Inotiv
CLOSE ×
×

Inotiv News

Inotiv

Inotiv Successfully Completes Financial Restructuring Process

Inotiv Announces Confirmation of Plan of Reorganization

Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth

Inotiv Provides Notice Regarding Cybersecurity Incident

Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update

Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026

Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery

Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update

Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™

Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025

Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results

Inotiv, Inc. to Participate in Three Investor Conferences in November 2025

Inotiv, Inc. to Participate in Three Investor Conferences in September 2025

CORRECTING and REPLACING - Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update

Advanced LNP Bioanalysis: Insights Shaping RNA-based Gene Therapy

Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025

Tapping Into the Full Therapeutic Potential of GLP-1

Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update

Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025

Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Provides Business Update

Inotiv, Inc. to Present at Jefferies Global Healthcare Conference 2025

Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million

Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million

Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares

Inotiv, Inc. Launches Proposed Public Offering of Common Shares

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update

Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024

Inotiv Awarded $1.8M Grant for Development of Novel Chronic Kidney Disease (CKD) Research Model

Inotiv, Inc. to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences

Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity

Inotiv Selected for the HRO Today’s Healthcare Talent Acquisition Team of the Year Award

Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference

Inotiv’s Lindsy Eickhoff Receives Two Awards at the PhUSE/FDA Computational Science Symposium 2024

Inotiv Reports Third Quarter Financial Results for Fiscal 2024 and Provides Business Update

Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024

Inotiv, Inc. Provides Business Updates

Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility

A Statement of Contrition From Inotiv

Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences

Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update

Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024

Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results

Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024

Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update

Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update

Inotiv, Inc. Announces Plan to Insource North American Transportation Operations

Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023

Inotiv Provides Business Updates and Upcoming Investor Conferences Update

Inotiv Ranked Number 127 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™

Inotiv, Inc. to Participate in Upcoming Investor Conferences

Inotiv, Inc. Announces Changes to its Board Composition

Inotiv’s Dr. Dan Liebler receives the RIFM Board of Directors Excellence in Science Award

Paper in the Regulatory Toxicology and Pharmacology journal co-authored by Inotiv scientists Melanie Foster and Dr. Debabrata Mahapatra

Inotiv Announces the Sale of its Israeli Businesses to Harlan Holdings Ltd.

Inotiv, Inc. to Participate in Upcoming September 2023 Investor Conferences

Inotiv Reports Third Quarter Financial Results for Fiscal 2023 and Provides Business Update

Inotiv, Inc. to Report Fiscal 2023 Third Quarter Financial Results and Host Conference Call on Thursday, August 10, 2023

Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference

Inotiv to Participate in May Investor Conferences

Inotiv Announces Second Quarter Fiscal 2023 Financial Results

Inotiv Expands Safety Pharmacology Offering to Include Cardiopulmonary Telemetry

Inotiv, Inc. to Report Fiscal 2023 Second Quarter Financial Results and Host Conference Call on Thursday, May 11, 2023

Paper co-authored by Inotiv’s Dr. Cheryl Hobbs receives Editor’s Choice award

Inotiv’s Dr. Judy Strickland, receives the Rosalind Franklin Society Special Award in Science

Inotiv Applauded by Frost & Sullivan as Key Competitor in the Bio-analytical Testing Services Market

Inotiv Announces First Quarter Fiscal 2023 Financial Results—Reiterates Select Full Year Fiscal 2023 Financial Guidance

Inotiv, Inc. to Report Fiscal 2023 First Quarter Financial Results and Host Conference Call on Monday, February 13, 2023

Inotiv Selected as a Winner of the 2023 Top Workplaces USA Award

Inotiv, Inc. Announces Changes to Board of Directors

Inotiv, Inc. Announces Fourth Quarter and Full Year Fiscal 2022 Financial Results

Inotiv, Inc. to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results and Host Conference Call on Tuesday, January 10, 2023

Inotiv, Inc. Provides Business Update and Select Preliminary Fiscal Year 2022 Financial Results

Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings

Inotiv, Inc. Announces Additional Site Consolidation Plan in the U.S.

Inotiv, Inc. to Report Fourth Quarter Fiscal 2022 Financial Results and Host Conference Call on Monday, December 12, 2022

Inotiv, Inc. to Participate in November Investor Conferences

Inotiv Announces Brennan Freeman as Vice President, Finance and Corporate Controller

Inotiv Announces Matt Vaneman as Vice President, Operational Excellence

Inotiv Announces Dr. Harutyun Avsaroglu as Executive Director, Global Laboratory Animal Resources

Inotiv, Inc. to Participate in September Investor Conferences

Inotiv, Inc. Announces Third Quarter Fiscal 2022 Financial Results—Increases Select Fiscal Year 2022 Financial Guidance

Inotiv, Inc. to Report Third Quarter Fiscal 2022 Financial Results and Host Conference Call on Wednesday, August 10, 2022

Inotiv, Inc. Continues to Expand Genetic Toxicology Offering with Support of GLP Assays at Rockville, MD, Location

Envigo Reaches Agreement with the U.S. Department of Justice and the U.S. Department of Agriculture to Resolve Civil and Administrative Complaints

Inotiv, Inc. Expands Protein/Peptide Bioanalytical Capabilities with Acquisition of Protypia, Inc.

Inotiv Appoints Lizanne Muller as Group President, RMS

Glenn Washer Joins Inotiv, Inc., as Group President, Safety Assessment

Inotiv Partners with Synexa Life Sciences to Establish Leading Global Provider of Full-spectrum, Preclinical and Clinical Biotherapeutics and Biomarker Analysis Solutions

Inotiv, Inc. Announces Site Closures and Consolidation Plans

Inotiv, Inc. to Participate in Upcoming Investor Conferences

Inotiv, Inc. Announces Second Quarter Fiscal 2022 Financial Results

Inotiv, Inc. to Report Second Quarter Fiscal 2022 Financial Results and Host Conference Call on Thursday, May 12, 2022

Inotiv, Inc. Bolsters Pathology Services with Acquisition of Histion, LLC

Inotiv Welcomes Fernanda Beraldi as General Counsel and Corporate Secretary

Inotiv Welcomes Technology Veteran Mo Dastagir as Chief Technology Officer

Inotiv, Inc. Announces First Quarter Fiscal 2022 Financial Results

Inotiv, Inc. Announces Expansion of Non-Human Primate Facilities and Services with Acquisition of Orient BioResource Center, Inc.

Inotiv, Inc. to Report First Quarter Fiscal 2022 Financial Results and Host Conference Call on Thursday, February 10, 2022

Inotiv, Inc. Announces Expansion of Safety Assessment Offerings with Acquisition of Integrated Laboratory Systems, LLC

Inotiv, Inc. Announces the Acquisition of the Rabbit Breeding and Supply Business of Robinson Services Inc. (“RSI”)

Inotiv, Inc. and Synexa Life Sciences Sign Letter of Intent to Establish Center of Excellence for Biotherapeutics and Biomarkers

Inotiv, Inc. Announces Fourth Quarter and Full Year Fiscal 2021 Financial Results

Inotiv, Inc. Announces the Launch of New Genetically Engineered Rodent Models for SARS-CoV-2 (COVID-19) Research

Inotiv, Inc. Reschedules Fourth Quarter Fiscal 2021 Financial Results and Conference Call for Thursday, December 16, 2021

Inotiv, Inc. Announces Select Preliminary Unaudited Financial Results for the Fourth Quarter and Full Year Fiscal 2021

Inotiv, Inc. to Report Fourth Quarter Fiscal 2021 Financial Results and Host Conference Call on Tuesday, December 7, 2021

Inotiv, Inc. Announces Opening of Newly-Constructed Laboratories at St. Louis Facility

Inotiv, Inc. Shareholders Approve Acquisition of Envigo

Inotiv, Inc. Completes Purchase of Envigo

Inotiv, Inc. completes purchase of Envigo

Inotiv, Inc. to Participate in Upcoming Investor Conferences

Inotiv, Inc. Announces Expansion of In Vivo Pharmacology Offering with Acquisition of Plato BioPharma, Inc.

Envigo announces collaboration with Biocytogen to distribute the B-NDG triple immunodeficient and humanizable mouse mode

Inotiv, Inc. Announces Closing of $125 Million Convertible Senior Notes Offering and Full Exercise of Option to Purchase Additional $15 Million of Notes

Inotiv, Inc. Prices Upsized $125 Million Convertible Senior Notes Offering

Inotiv, Inc. Announces Proposed Convertible Senior Notes Offering

Inotiv, Inc. and Envigo propose to join forces to enhance research and drug discovery solutions

Inotiv, Inc. to Participate in the 2021 Colliers Institutional Investor Conference

Inotiv, Inc. Announces Third Quarter Fiscal 2021 Financial Results

Inotiv, Inc. Announces Acquisition of Gateway Pharmacology Laboratories

Inotiv, Inc. to Report Third Quarter Fiscal 2021 Financial Results and Host Conference Call on Wednesday, August 11, 2021

Inotiv Acquires Laboratory Instrumentation for Discovery and Development of Novel Therapies

Inotiv Acquires Genetic Toxicology Assets from MilliporeSigma’s BioReliance® portfolio

Inotiv, Inc. Broadens Pathology Services to Include Medical Device Pathology and Hires Nicolette Jackson to Lead Effort

Inotiv Set to Join Russell 3000® Index and Russell 2000® Index

Inotiv Announces Purchase of St. Louis Facility and Plans to Expand Capacity

Kenneth Swart, Ph.D., Joins Inotiv as Vice President, Bioanalytical Sciences to Drive Growth of Expanding Laboratory Solutions Offerings

Envigo celebrates 90 years of working together to build a healthier and safer world

Inotiv, Inc. Announces Second Quarter Fiscal 2021 Financial Results

Inotiv, Inc. Announces Debt Financing and Completion of Acquisitions of HistoTox Labs, Inc. and Bolder BioPATH, Inc.

Inotiv, Inc. to Report Second Quarter Fiscal 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021

Inotiv, Inc. Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares

Inotiv, Inc. Announces Pricing of Public Offering of 2,647,059 Common Shares

Inotiv, Inc. Announces Select Preliminary Unaudited Financial Results for Second Quarter and Year to Date Fiscal 2021

Inotiv, Inc. Announces Proposed Public Offering of Common Shares

Inotiv, Inc. Announces Plan to Expand the Company’s Internal Operations

Inotiv, Inc. Announces Expansion of Pharmacology and Pathology Offerings with Agreement to Purchase Bolder BioPATH, Inc

Inotiv, Inc. Enhances Histopathology Offering with Announcement of Agreement to Purchase HistoTox Labs, Inc.

Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette, IN

Inotiv, Inc. Announces Partnership with PhoenixBio Co., Ltd. to Expand Discovery Pharmacology Offering

Bioanalytical Systems, Inc., doing business as Inotiv, to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference

Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv, Inc.

Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology

Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Laboratory Infrastructure and Data and Study Management Technologies

Bioanalytical Systems, Inc., doing business as Inotiv, Appoints Greg Beattie as Chief Operating Officer

Bioanalytical Systems, Inc., Announces First Quarter Fiscal 2021 Financial Results

Bioanalytical Systems, Inc., to Report First Quarter Fiscal 2021 Financial Results and Host Conference Call on Tuesday, February 9, 2021

Inotiv Broadens Pathology Service Offerings

Daniel Smeak, DVM, ACVS, Joins Inotiv as Vice President, Surgical Models

BASi Releases Earnings for Fourth Quarter of Fiscal 2020

BASi to Release Earnings for Fourth Quarter of Fiscal 2020 on Monday, December 21, 2020

Andrew N. Alexander, DVM, Ph.D., MBA, DABT, Joins Inotiv as Vice President, Pharmacology and Toxicology Operations

BASi to Participate in H.C. Wainwright Investment Conference

BASi Releases Earnings for Third Quarter of Fiscal 2020

I.M. (Gina) Grossi, Ph.D., Joins Inotiv as Vice President of Toxicology to Drive Growth of Expanding Toxicology Business

BASi Releases Earnings for Second Quarter of Fiscal 2020

Diane Tutko Francisco, Ph.D., Joins Inotiv to Lead Client Experience Team

BASi Announces Borrowing under Paycheck Protection Program

Bioanalytical Systems, Inc. d/b/a Inotiv Appoints Beth A. Taylor as New Chief Financial Officer

BASi Releases Earnings for First Quarter of Fiscal 2020

Inotiv Launches Website for Newly Unified Contract Research Services

BASi Closes Fiscal 2019 with Strong Fourth Quarter

Inotiv, a BASi Company, Announces Closing of Pre-Clinical Research Services Transaction, Including New Financing to Fund the Transaction and Expand Discovery and DMPK Business

Inotiv, a BASi Company, Announces Closing of Pre-Clinical Research Services Transaction, Including New Financing to Fund the Transaction and Expand Discovery and DMPK Business

BASi Launches Rebrand of its Contract Research Services Business Under the Name Inotiv

BASi Announces Expansion into Surgical Models and Medical Devices with Agreement to Purchase Pre-Clinical Research Services

BASi Announces Expansion into Surgical Models and Medical Devices with Agreement to Purchase Pre-Clinical Research Services

Envigo to acquire research models business unit from Horizon

Stewart B. Jacobson, DVM, DACVP, Joins BASi as Vice President, Pathology, Filling Key Scientific Leadership Position

William D. Pitchford Joins BASi as Chief Human Resources Officer, as the Company Invests in Unifying and Strengthening Corporate Culture

LabCorp and Envigo complete innovative transactions

Researchers Generate Better Data with BASi’s Redesigned Raturn™

CORRECTED PRESS RELEASE: BASi Acquires the Smithers Avanza Toxicology Services Business Unit to Support Growing Toxicology Business and Broaden Scientific Talent

BASi Acquires the Smithers Avanza Toxicology Services Business Unit

LabCorp and Envigo sign innovative agreement to expand Covance's nonclinical drug development capabilities and create an independent research models provider

J. Scott Daniels, PhD, Joins BASi as Senior Vice President of DMPK, Filling Key Scientific Leadership Position

BASi Appoints Joe Flynn as Chief Commercial Officer

BASi Appoints Senior Contract Research Executive, D. Thomas Oakley, as Chief Operating Officer

BASi Elects Entrepreneur, Who Has Led BASi Turnaround and Recent Growth, as President and Chief Executive Officer and a Director

BASi Names John E. Sagartz Chief Strategy Officer

BASi Breaks Ground on Expansion of GLP Toxicology Facility in Indiana

BASi Announces Appointment of John E. Sagartz to Board of Directors

Seventh Wave Laboratories Combine Operations to Provide Broader Solutions and Greater Scientific Expertise to Clients

James Bourdage to Retire as BASi VP of Bioanalytical Operations; Michael Baim Named as Successor

BASi and Phlebotics Form Strategic Alliance; Continuing a Commitment to Automated Blood Sampling

Bolstering Preclinical PK/PD Operations: BASi Hires Karen L. Rogers, DVM, DACLAM, CPIA as Attending Veterinarian

Envigo to Expand Livermore, California Research Model Surgical Facility to Meet Rising Demand from West Coast Biopharmaceutical Companies

BASi Announces Enhanced Bioequivalence Capabilities

Envigo implements first-in-class surgical model tracking system

Steady Growth Spurs Plans for BASi Expansion of GLP Toxicology Facility in Indiana

Envigo partners with Atlantic Pollination and The Red Beehive Company to provide customers with specialist ecotox expertise

Chemical Industry Awards short-list Envigo

Envigo launches R2G2 double knockout mouse model

Envigo expands R&D capabilities in non-animal technologies to meet regulatory and market requirements for in vitro assays

Envigo’s fully validated highly sensitive method enables completion of thyroid hormone tests in accordance with OECD guidelines

Envigo launches 'biocides insights' to help identify regulatory pathways

Successful completion of ecotox laboratory enhancements for Envigo in Shardlow

Subscribe to updates from Inotiv

Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.

Subscribe now